Lactose is the most commonly used excipient in carrier-based dry powder inhalation (DPI)
formulations. Numerous inhalation therapies have been developed using lactose as a …

Pulmonary drug delivery is a highly attractive topic for the treatment of infectious lung
diseases. Drug delivery via the pulmonary route offers unique advantages of no first-pass …

Dry powder inhalation therapy has been shown to be an effective method for treating
respiratory diseases like asthma, Chronic Obstructive Pulmonary Diseases and Cystic …

The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes
respiratory failure. Despite numerous clinical trials, there are no molecularly targeted …

Pulmonary drug delivery is currently the focus of research and development because of its
potential to produce maximum therapeutic benefit to patients by directing the drug straight to …

Regulatory science for generic dry powder inhalation products worldwide has evolved over
the last decade. The revised draft guidance Metered Dose Inhaler (MDI) and Dry Powder …

Tuberculosis (TB) is caused by Mycobacterium tuberculosis (M. tb) and is the second
leading cause of death from an infectious disease globally. The disease mainly affects the …

Today, the principle of research and development is pulmonary drug delivery due to the
potential for maximizing therapeutic effects for patients by direct drug targeting the pathology …

The quick advancement in pulmonary medicines, delivery mechanisms, and inhaler device
techniques in the last few years has recommended that the microstructural understanding of …

The effect of capsule aperture size on the aerosol performance of lactose blend formulation
was studied using Foradil®(containing 12 μg of formoterol fumarate (FF 1) and 24 mg of …